Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Bristol Myers Squibb < Previous 1 2 3 4 5 6 7 8 9 10 Next > CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma April 26, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Reports First Quarter Financial Results for 2024 April 25, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster April 22, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) April 08, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society April 06, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society April 06, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy April 05, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY TSVT European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) April 02, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals April 02, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung… March 28, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease March 28, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes March 26, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio March 25, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma March 20, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma March 20, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign March 19, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio March 18, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy March 15, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY TSVT U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) March 14, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024 March 11, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma March 07, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb to Participate in Upcoming Investor Conferences March 06, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Announces Dividend March 01, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis February 29, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference February 26, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform February 26, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS) February 23, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer February 23, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY RYZB U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or... February 20, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes February 14, 2024 From Bristol Myers Squibb Via Business Wire Tickers BMY < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.